Chongqing Sidemu Biotechnology

Chongqing Sidemu Biotechnology, also known as ImmunCyte Life Science, is a clinical-stage biotechnology company based in Chongqing, China, specializing in advanced Natural Killer (NK) cell therapies. The company focuses on developing "off-the-shelf" universal CAR-NK products derived from cord blood to treat infectious diseases and oncology. Its most prominent program is a dual-targeting NKG2D-ACE2 CAR-NK therapy, which was advanced into Phase 1/2 clinical trials for the treatment of COVID-19 and related viral pneumonia. By engineering cells to express specific receptors and cytokines like IL-15, the company aims to enhance the persistence and efficacy of innate immune responses against pathogens and tumors. Sidemu is recognized in global pipeline reports as a key innovator in the emerging NK cell therapy landscape.